TrialA Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Trial details
- Registry ID
- NCT03987295
- Phase
- Phase 2
Drug research
AL001
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)NCT03987295 | ALEC | Phase 2 | Completed | 2024-06-05Actual |
| A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALSNCT05053035 | ALEC | Phase 2 | Terminated | 2022-10-28Actual |
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
Trial details
- Registry ID
- NCT05053035
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |